The Liddy Shriver Sarcoma Initiative helping those dealing with sarcoma.                      HOME
Liddy's Story
Sarcomas
Clinical Trials
ESUN
Funded Research
Sarcoma Calendar
Initiatives
Personal Journeys
Links
News
Donations
Volunteer
First Time Visitors
Searching Our Website
Guest Book

Refractory/Recurrent
Up
Exatecan
Gemcitabine+Docetaxel
Irinotecan+Temozolomide
Lung Matastases
Platinum Compounds
Poor Response
Stem Cell Rescue
Topotecan+Cyclophoshamide
Unknown Effect

Gemcitabine+Docetaxel
 

Basic Information on Gemcitabine

  • Gemcitabine is also called Gemzar

  • Has been used successfully with pancreas and non-small cell lung cancer

  • Is an antimetabolite

Basic Information on Docetaxel  

  • Docetaxel is also called Taxotere

  • Used for breast cancer and non-small cell lung cancer

  • Is an antineoplastic

Research Results: Ewing's Sarcoma  

  • 2002 poster on gemcitabine and docetaxel in sarcoma; Ewing's sarcoma had a 1/1 response. (University of Michigan Cancer Center)

Research Results: non-Ewing's Sarcoma  

  • 2000 summary of trial in Israel, stating that gemcitabine was effective in achieving stabilization of sarcomas resistant to standard chemotherapies; 8/18 partial, minimal or stable sarcomas.  (No Ewing's on study)

  • 1999 abstract on gemcitabine for advanced soft tissue sarcomas; the dosage might have been too low for response

Current and Closed Clinical Trials  

  • Gemcitabine and docetaxel Phase 2 trial at MSK in New York City (another description) (for adults); Ewing's sarcoma is not allowed

  • Gemcitabine and docetaxel Phase 1 trial  in New Hampshire. The PI was at MSK.  The cycles is 2 weeks long; it is a dose-escalation study of docetaxel (for adults)